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Introduction
Anaplastic lymphoma kinase-positive anaplastic large cell lymphoma (ALK + ALCL), a distinct type of non-Hodgkin's lymphoma of T/null-cell lineage, primarily affects children and young adults and constitutes 10-30% of all pediatric lymphomas. 1 Most ALK + ALCL tumors carry the t(2;5)(p23;35) cytogenetic abnormality, which places the ALK (anaplastic lymphoma kinase) gene under the regulation of the NPM (nucleophosmin) gene promoter. The resulting fusion protein (NPM-ALK) has constitutively active tyrosine kinase activity, which has been shown to be critically important for its transformation ability. [2] [3] [4] NPM-ALK is known to bind and activate a host of cell signaling pathways, including those of JAK/STAT3, 3, 5 Ras/ERK 6 and PI3K/AKT, [7] [8] all of which are known to regulate important cellular functions such as cell cycle progression and cell survival. Of these, the signal transduction and activation of transcription 3 (STAT3) pathway is the best characterized; constitutive activation of STAT3 has been shown to be central to the pathogenesis of ALK + ALCL. [9] [10] [11] b-catenin is a multifunctional protein that serves as an adhesion molecule in epithelial cells and a transcriptional factor in the context of the Wnt canonical pathway. [12] [13] When the Wnt canonical pathway is inactive, b-catenin is bound to GSK3b in the so-called 'destruction complex' that promotes serine/threonine phosphorylation of b-catenin and facilitates its proteasomal degradation. When the Wnt canonical pathway is activated, GSK3b is inactivated, leading to decreased serine/threonine phosphorylation of bcatenin and enhancing its stabilization. Once accumulated in the cells, b-catenin translocates to the nucleus and forms a complex with the TCF/LEF family of transcription factors to initiate the transcription of various target genes including cyclin D1, c-myc and c-jun. 12, 14 b-catenin has been recently shown to play a role in the survival and proliferation of normal murine CD4 + T cells. 15 In benign human lymphocytes, the expression level of b-catenin is regulated through a posttranslational mechanism. Specifically, this protein is continuously degraded in normal resting peripheral blood lymphocytes, 16 such that b-catenin is undetectable by western blot studies. [16] [17] [18] Although deregulated b-catenin signaling has been found in many solid tumors, particularly colonic cancer, 12 relatively few studies have elucidated its role in hematologic malignancies; evidence of b-catenin deregulation has been previously found in subsets of T-cell lymphomas, mantle cell lymphoma and myeloid malignancies. [19] [20] [21] [22] [23] Directly relevant to this study, a number of oncogenic tyrosine kinases found in several types of hematologic malignancies, such as BCR-ABL and C-KIT, were found to induce tyrosine phosphorylation and stabilization of bcatenin, and increase its transcriptional activity. 21, [23] [24] In view of the fact that oncogenic tyrosine kinases found in hematologic cancers can stabilize/activate b-catenin and increase its transcriptional activity, we questioned whether NPM-ALK, also an oncogenic tyrosine kinase found exclusively in ALK + ALCL, exerts similar effects on b-catenin. Thus, in this study, we investigated the functional status and biological significance of b-catenin in this type of cancer.
Design and Methods

Anaplastic lymphoma kinase-positive anaplastic large cell lymphoma cell lines and patients' samples
The three NPM-ALK-expressing ALCL cell lines, Karpas 299, SUPM2, SU-DHL-1, have been described previously. 25 Jurkat, a human T-cell acute lymphoblastic leukemia cell line, was purchased from American Type Culture Collection (Manassas, VA, USA) and cultured in RPMI-1640 (Gibco, Carlsbad, CA, USA) containing 2 mM of L-glutamine supplemented with 10% fetal bovine M. Anand et al. 254 haematologica | 2011; 96(2) . The lymphoma cells of both cases also showed some cytoplasmic staining, with the case illustrated in (B) showing stronger cytoplasmic staining than the case illustrated in (A). Normal tonsillar lymphoid tissues, used as a negative control, showed no detectable staining, whereas bright membranous staining of the normal squamous epithelial lining was identified (C) and (D), 100X and 1000X magnification, respectively). (E) Nuclear-cytoplasmic fractionation and western blot showed the presence of nuclear (N) and cytoplasmic (C) portions of b-catenin in all three ALK + ALCL cell lines. b-tubulin and HDAC-1 were used as the controls to assess the efficiency of the cytoplasmic and nuclear fractionation, respectively. (F) Immunofluorescence and confocal microscopy showed the presence of nuclear b-catenin (Alexa fluor 488) in ALK + ALCL cell lines when they were stained using the anti-b-catenin antibody; no signal was seen when only the isotype control (IgG) was used. serum (Gibco). GP293 cells were cultured in Dulbecco's modified Eagle's medium (Gibco) containing 4 g/L glucose supplemented with 10% fetal bovine serum. All ALK + ALCL primary tumors were diagnosed at the Cross Cancer Institute and the diagnostic criteria were based on those described in the World Health Organization Classification Scheme. 1 Immunohistochemistry showed both nuclear as well cytoplasmic ALK staining in all cases. The use of these tissues was approved by our Institutional Ethics Committee.
Antibodies, plasmids and drugs
Antibody against ALK (1:500) was bought from Dako, Glostrup, Denmark and b-catenin (clone 14, 1:1000) was purchased from BD Transduction Laboratories, Lexington, KY, USA. Antibodies against b-catenin (whole antiserum, for immunofluorescence and immunoprecipitation studies), HDAC-1 and b-actin (1:10,000) were purchased from Sigma Aldrich (St. Louis, MO, USA). Anti-cjun (1:1000) was purchased from Cell Signaling (Danvers, MA, USA), while antibodies against total STAT3 and pSTAT3Tyr
705
(1:1000), α-tubulin (1:1000), phospho-tyrosine (1:2000), phosphob-catenin Y86 and phospho-b-catenin Y654 (1:1000) were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). The plasmid carrying NPM-ALK was a kind gift from Dr. S Morris, St. Jude Children's Research Hospital (Memphis, TN, USA) and the NPM-ALK construct was cloned into the pCDNA3 vector (Invitrogen, Burlington, Ontario, Canada). The 'kinase-dead' mutant of NPM-ALK (210K>R) has been previously described 26 and was a gift from Dr. HM Amin (M.D. Anderson Cancer Center, Houston, TX, USA).
Subcellular protein fractionation and western blot
For subcellular protein fractionation, we employed a kit purchased from Active Motif (Carlsbad, CA, USA) and followed the manufacturer's instructions. Cell lysates for western blots were prepared as follows: cells were washed with phosphate-buffered saline (PBS), and cellular proteins were solubilized using RIPA buffer containing 150 mM NaCl, 1% NP40, 0.5% deoxycholic acid, 0.1% sodium dodecylsulfate (SDS), 50 mM Tris pH8.0 which was supplemented with 40 μg/mL leupeptin, 1 μM pepstatin, 1 mM 4-(2-aminoethyl)-benzenesulfonyl fluoride (AEBSF) and 0.1 mM phenylmethylsulfonyl-fluoride (PMSF). The protein concentration of the samples was determined using a BCA Protein assay kit (Pierce, Thermo Fisher Scientific Inc., Rockford, IL, USA). Cell lysates were then electrophoresed on 8% or 10% SDS-polyacrylamide gels and transferred onto nitrocellulose membranes (Bio-Rad, Richmond, CA, USA). The membranes were blocked with 5% milk in Tris buffered saline (TBS)-0.1% Tween buffer for 1 h (20 mM Tris-HCL, pH=7.6, 150 mM NaCl) and then incubated with the primary antibodies overnight at 4°C. After three washes with TBS-0.1% Tween, the membranes were incubated with the specific secondary antibody conjugated with horseradish peroxidase (Cedarlane Laboratories, Burlington, Ontario, Canada) for 1 h at room temperature. This was followed by three washes with TBS-0.1% Tween and the protein was detected using a chemiluminescence detection kit (Pierce).
Immunofluorescence and confocal microscopy
Cells were grown on cover slips coated with poly-L-lysine (Sigma Aldrich) in a six-well plate and fixed with 3% paraformaldehyde in PBS (pH 7.4). Cell were rinsed three times with PBS, permeabilized with Triton X100, washed again with PBS, and incubated with 200 μL of anti-b-catenin antibody (1:50, Sigma Aldrich) overnight at room temperature in a humidified chamber. The cover slips were rinsed three times in PBS and incubated with secondary antibody conjugated with Alexa Fluor 488 (Invitrogen) at a 1:250 dilution for 1 h at room temperature. After three rinses in PBS, the cover slips were mounted on a slide using 
TOP/FOP luciferase reporter assay
To assess the transcriptional activity of b-catenin in ALK + ALCL, we employed the TOP/FOP reporter system using the dualluciferase kit (Dual-Glo TM Luciferase Assay System, Promega, Madison, WI, USA). ALK + ALCL cells (10¥10 6 /500 μL RPMI) were transiently transfected with 1 μg of constitutively active vector encoding Renilla luciferase (Promega) and 10 μg of b-cateninresponsive firefly luciferase reporter plasmid TopFlash (Millipore, Billerica, MA, USA) or the negative control FopFlash (Millipore) using the Electro square electroporator BTX ECM 800 (225V, 8.5 ms, 3 pulses) (Holliston, MA, USA). Cells were harvested after 24 h in culture and both firefly and Renilla luciferase activity was measured in duplicate/triplicate according to the manufacturer's instructions. The firefly luciferase activity was normalized against the Renilla luciferase activity and fold increase in TOPFlash activity compared to FOPFlash is reported. To assess the function of NPM-ALK on b-catenin transcriptional activity, Karpas 299 cells were cotransfected with TopFlash or FopFlash and short interfering RNA (siRNA) ALK using the BTX electroporator (225V, 8.5 ms, 3 pulses). Cells were harvested after 48 h for luciferase measurements.
Co-immunoprecipitation and immunoprecipitation
Cells were washed with cold PBS and lysed using Cell Lytic Buffer M (Sigma) supplemented with protease inhibitor (Nacalai Inc, San Diego, CA, USA), a phosphatase inhibitor cocktail (Calbiochem, EMD Biosciences, Darmstadt, Germany) and 0.1 mM PMSF (Sigma). After incubating on ice for 30 min, the lysate was centrifuged at 15000g for 15 min. Two micrograms of the primary antibody were added to 500 μg of protein lysate and rotated overnight at 4°C. Control samples with the primary antibody omitted were also included in each test. Fifty microliters of protein A/G Sepharose beads (Santa Cruz Biotechnology) were added to both the test and control lysates and rocked for 2 h at 4°C. The beads were then washed three times with cold PBS, followed by one wash with cold cell lysis buffer. The bound protein was eluted from the beads in 20 μL of SDS protein loading buffer by boiling for 5 min at 100°C and then processed for western blotting. Lysis and washing steps were modified for the immunoprecipitation of the core protein only. To avoid precipitation of the binding partners, the cells were lysed in RIPA buffer and the beads were washed three times with PBS followed by one wash with RIPA buffer.
Immunohistochemistry
Immunohistochemistry was performed using standard techniques. 20 Briefly, formalin-fixed, paraffin-embedded tissue sections or tissue micro-arrays of 4 μM thickness were deparaffinized and rehydrated. Heat-induced epitope retrieval was performed using citrate buffer (pH 6.0) and pressure cooked in a microwave for 20
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haematologica | 2011; 96(2) min. The endogenous peroxidase activity was blocked using 0.3% H2O2 in methanol for 5 min. Tissue sections were then incubated with mouse monoclonal anti-b-catenin antibody (BD Transduction Laboratories, 1:50) overnight at 4°C in a humidified chamber. After two washes with PBS, tissue slides were incubated with biotinylated-linked universal secondary antibody and subsequently with streptavidin-horseradish peroxidase complex according to the manufacturer's instructions (LSAB+ system, Dako). Tissue sections were incubated with 3,3'-diaminobenzidine/H2O2 (Dako) for color development and counter-stained with hematoxylin. Tumor cells showing definitive b-catenin nuclear staining were regarded as positive. Tumors with isolated cytoplasmic staining/membrane staining were considered negative. In these experiments isotypematched purified IgG served as a negative control.
Short interfering RNA and transfections
siRNA (SMARTpool) for ALK and scrambled siRNA (SMARTpool) were purchased from Dharmacon (Lafayette, CO, USA). Two unrelated b-catenin-specific siRNA purchased from Sigma were pooled and transient transfections of ALK + ALCL cells (5¥10 6 cells) was performed using the Electro square electroporator BTX ECM 800 (225V, 8.5 ms, 3 pulses). Two hundred picomole of pooled siRNA or scrambled control were used per million ALK + ALCL cells. The efficiency of target gene inhibition was assessed using western blotting.
Assessment of cell growth
ALK + ALCL cells transfected with b-catenin-specific siRNA or scrambled control were plated at a density of 10,000/mL or 20,000/mL and cultured for 5 days. Cells were counted on days 2, 3 and 5 using trypan blue (Sigma) and the results are expressed as total number of viable cells. Seven replicates of the MTS assay (Promega) were done according to the manufacturer's instructions. The absorbance was recorded by a BioRad spectrophotometer at day 5 of cell culture.
Results
b-catenin is expressed and localized to the nucleus in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma cell lines and tumors
Using immunohistochemistry applied to paraffinembedded tissues, the expression of b-catenin was examined in a cohort of ALK + ALCL tumors (n=12). The results are illustrated in Figure 1 . We found 10 cases (83%) showing a definitive nuclear expression pattern. While cytoplasmic staining of b-catenin was frequently seen, the intensity was variable among cases ( Figure 1A,B) . Tonsillar lymphoid tissue, used as a negative control, showed no appreciable staining; in contrast, squamous epithelial cells showed bright membranous staining ( Figure 1C,D) .
In contrast to normal peripheral blood T cells that had barely detectable b-catenin (Online Supplementary Figure  S1 ), ALK + ALCL cells showed a relatively high level of bcatenin protein. As shown in Figure 1E , subcellular fractionation studies were performed using three ALK + ALCL cell lines: Karpas 299, SUPM2 and SU-DHL-1. Although a relatively high level of b-catenin was present in the cytosol, b-catenin could also be clearly detected in the nuclear fraction of these cells. α-tubulin (a cytoplasmic protein) and HDAC1 (a nuclear protein), served as markers to assess the efficiency of subcellular fractionation and, as expected, these were detected only in the cytoplasmic and nuclear fractions, respectively. To confirm the nuclear localization of b-catenin, we employed confocal microscopy, which clearly revealed the nuclear localization of b-catenin in SU-DHL-1 and SUPM2 cells ( Figure  1F ).
b-catenin is transcriptionally active in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma cell lines
To demonstrate directly that b-catenin is transcriptionally active in ALK + ALCL cells, we used the TOPFlash/FOPFlash luciferase reporter system. As shown in Figure 2A 
b-catenin down-regulation decreases the expression of STAT3 and pSTAT3 levels
Since STAT3 has been reported to be a b-catenin target gene in esophageal squamous cell carcinoma cells, 27 we hypothesized that the mechanism underlying the cell growth-promoting effects of b-catenin in ALK + ALCL may be mediated via STAT3, a signaling protein previously shown to be highly activated and important in the pathogenesis of ALK + ALCL. 3, 9, 11 In keeping with this hypothesis, transfection of pooled siRNA specific for b-catenin resulted in a substantial (in the range of 40-60%) down-regulation of the total STAT3 protein level in all three cell lines. We also observed a down-regulation of pSTAT3, the level of reduction of which approximated that of STAT3 in all three cell lines ( Figure 4A,B) . In contrast, the expression level of cjun was not appreciably changed. To rule out the possibility of an off-target effect for this pooled siRNA, we repeated the experiments using the two individual and unrelated siRNA species in the pool separately, and we showed similar results regarding the changes in the STAT3 and pSTAT3 expression (Online Supplementary Figure S2) . The regulation of STAT3 expression level by b-catenin appeared to be transcriptional, as the STAT3 mRNA levels assessed using realtime polymerase chain reaction were significantly decreased in Karpas 299 and SUPM2 cells ( Figure 4C ). Of note, the decrease in STAT3 mRNA was comparable to that of the protein (i.e. approximately 40-50%).
The physical and functional interaction between nucleophosmin-anaplastic lymphoma kinase and b-catenin
As mentioned above, a number of oncogenic tyrosine kinases have been previously shown to bind to and activate b-catenin by increasing its tyrosine phosphorylation, stability and nuclear translocation. Thus, we asked whether NPM-ALK, an oncogenic tyrosine kinase playing a central role in ALK + ALCL, also exerts similar effects on b-catenin. In ALK + ALCL cell lines, we found that NPM-ALK was pulled down with b-catenin in all three ALK + ALCL cell lines by co-immunoprecipitation ( Figure  5A ). However, probing with an anti-phosphotyrosine antibody revealed only a barely detectable level of tyrosine phosphorylation of b-catenin, compared to the negative controls. When we knocked down NPM-ALK expression in Karpas 299 and SUPM2 cells using siRNA, we did not find any detectable change in the protein level or subcellular localization of b-catenin ( Figure 5B ). In keeping with these results, when we transiently transfected Jurkat cells with NPM-ALK, we found that ectopic NPM-ALK expression resulted in a dramatic up-regulation of pSTAT3 (a commonly used surrogate marker of the tyrosine kinase activity of NPM-ALK) but no detectable increase in the total protein level, nuclear translocation or tyrosine phosphorylation of b-catenin in Jurkat cells ( Figure 5C-E) . Similar results were obtained with GP293 cells, an embryonic kidney cell line that expresses a relatively high level of b-catenin. The lack of increased tyrosine phosphorylation of b-catenin correlated with the observation that these two molecules did not co-immunoprecipitate with each other in GP293 cells (data not shown). Interestingly, when we co-transfected b-catenin and NPM-ALK in GP293 cells, we observed co-immunoprecipitation of these two proteins ( Figure 5F ); in addition, the introduced b-catenin was pulled down and heavily tyrosine phosphorylated by NPM-ALK but not by the 'kinase-dead' mutant of NPM-ALK as shown by probing with total phospho-tyrosine antibody and confirmed by phospho-specific antibodies (b-catenin p Y86 and b-catenin p
Y654
) which specifically recognize tyrosine phopshorylation of residues Y86 and Y654 of b-catenin ( Figure 5G-H) .
Nucleophosmin-anaplastic lymphoma kinase significantly modulates the transcriptional activity of b-catenin in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma cells Although NPM-ALK did not induce any appreciable change in the protein level and nuclear translocation of bcatenin, we investigated whether NPM-ALK modulates the transcriptional activity of b-catenin. Using the TOPFlash/FOPFlash luciferase reporter system, we assessed the transcriptional activity of b-catenin in the presence or absence of ALK siRNA. To rule out the possibility of an off-target effect of siRNA, Jurkat cells, which have been previously shown to have b-catenin expression and activation, 17 were treated similarly with ALK-specific siRNA. We observed a significant decrease in the transcriptional activity of b-catenin when NPM-ALK expression was down-regulated in Karpas 299 cells ( Figure 6A ); in contrast, this remained unchanged in Jurkat cells treated with ALK-specific siRNA ( Figure 6B ). Experiments were performed in triplicate, and the results from a representative experiment are shown in Figure 6 . Discussion b-catenin, the critical effector of the Wnt pathway, regulates a number of key processes during development including proliferation, differentiation and cell fate determination, as well as tissue homeostasis in adults. b-catenin is normally localized to the cell adhesion junctions in epithelial cells and its abnormal cytplasmic/nuclear stabilization drives uncontrolled transcription of target genes (including c-jun, cyclin D1, c-myc, survivin, and MMP-7) regulating cell proliferation, survival and cell adhesion. 12 In view of its biological importance, it is not surprisingly that deregulation of b-catenin has been linked to the pathogenesis of a number of human cancers, particularly those with an epithelial cell origin. 28 Illegitimate activation of b-catenin has also been reported in several types of hematopoietic cancers. 19, [29] [30] [31] Nevertheless, the functional status and biological role of b-catenin have never been investigated in ALK + ALCL. In this study, we found that b-catenin is transcriptionally active in ALK + ALCL cells, and this conclusion is supported by its nuclear localization and the results from the TOP/FOP luciferase assay. As discussed, this is contrast with the situation in normal peripheral blood T cells, in which b-catenin is continuously degraded such that it is undetectable by western blot studies. [16] [17] [18] Our data also support the concept that b-catenin is biologically significant in ALK + ALCL, as down-regulation of this protein using siRNA significantly reduced the growth of ALK + ALCL cells. These results are reminiscent of the observation made recently that b-catenin plays an important and complex role in the biology of normal mouse T cells. 15 Our results also uncovered a cross-talk between b-catenin and STAT3 in ALK since the level of reduction at the mRNA level was similar to that seen at the protein level. This conclusion is in keeping with the previous report that the STAT3 promoter contains multiple TCF binding sites. 27 Moreover, the observation that the down-regulation of b-catenin resulted in a similar level of decrease in both STAT3 and pSTAT3 suggests that the down-regulation of pSTAT3 is simply related to that of total STAT3 levels. This observation suggests that b-catenin is a regulator of STAT3 activation via its control over the total expression of STAT3. Since there are many known factors contributing to STAT3 activation in ALK + ALCL, including stimulation by multiple cytokines 5, 32 and various tyrosine kinases, 3, 33 as well as a defective negative feedback system, [34] [35] it is not too surprising that the total STAT3 protein level is the limiting factor for determining the level of STAT3 phosphorylation/activation. On the other hand, the expression of c-jun, another known bcatenin target gene, remained unchanged in these cells. This is most likely related to the fact that modulation of various target genes by various transcriptional factors is often cell-type specific.
The etiology underlying the constitutive activation of bcatenin in ALK + ALCL is incompletely understood. In chronic myeloid leukemia, there is evidence that the oncogenic, constitutively active tyrosine kinase BCR-ABL contributes to the stabilization of b-catenin by increasing its tyrosine phosphorylation, which is associated with increased nuclear translocation and transcriptional activity. 23 Given that NPM-ALK is also a constitutively active tyrosine kinase, we investigated whether NPM-ALK can exert similar effects on b-catenin as BCR-ABL does. The results are rather surprising. Despite the physical interaction between NPM-ALK and b-catenin, b-catenin was found to be minimally tyrosine phosphorylated in ALK + ALCL cells. Down-regulation of NPM-ALK using siRNA did not result in any detectable change in the expression or nuclear localization of b-catenin. The lack of tyrosine phosphorylation of b-catenin by NPM-ALK was further supported by the transfection experiments using Jurkat cells. Results from the experiments using GP293 cells are interesting. While transfection of NPM-ALK alone into these cells resulted in no evident physical or functional interaction with the endogeneous b-catenin, co-transfection of NPM-ALK and b-catenin into these cells did result in their physical interaction and a marked increase in tyrosine phosphorylation of b-catenin. Overall, these data seem to indicate that even if NPM-ALK can induce tyrosine phosphorylation and nuclear localization of bcatenin in epithelial cells, this mechanism is likely not effective in ALK + ALCL cells. In this regard, it is interesting to note that NPM-ALK can interact with a protein without inducing its tyrosine phosphorylation. 36, 37 Overall, our data suggest that the interaction between oncogenic tyrosine kinases and various cellular signaling proteins may be more complex than previously believed.
Despite the fact that NPM-ALK does not seem to alter protein level or nuclear translocation of b-catenin in ALK + ALCL cells, our results showed that NPM-ALK regulates the transcriptional activity of b-catenin. The mechanism underlying this regulation is unclear, but it is likely that the effect of NPM-ALK on b-catenin transcriptional activity is indirect. Since the transcriptional activity of bcatenin requires co-factors of the TCF/LEF system, it is possible that NPM-ALK regulates the activity of b-catenin through the modulation of other co-factors or by modulating the activity of other pathways. Further studies to investigate this level of regulation may be warranted.
In conclusion, we demonstrate that b-catenin is constitutively activated in ALK + ALCL. Our data also demonstrate that b-catenin is important in the pathogenesis of ALK + ALCL, in part by increasing the expression of STAT3. Thus, our study has revealed a novel functional link between two oncogenic signaling proteins in ALK + ALCL. Lastly, our results suggest that the interaction between oncogenic tyrosine kinases and various cell signaling proteins may be more complex than previously believed. 
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